What is the 13F Pro Quality Score for BLFS?

13F Pro ranks BIOLIFE SOLUTIONS INC (BLFS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BLFS's current score at https://13fpro.ai/company/BLFS (free sign-up required for the full ranking).

Which hedge funds own the most BLFS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BLFS include T. Rowe Price Investment Management,, BlackRock,, Casdin Capital,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/BLFS as soon as new 13F filings post.

Where does 13F Pro source BLFS data?

All BIOLIFE SOLUTIONS INC fundamentals and ownership data come directly from SEC EDGAR. BIOLIFE SOLUTIONS INC files with the SEC under CIK 834365. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BLFS in?

BIOLIFE SOLUTIONS INC (BLFS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BLFS research updated on 13F Pro?

BLFS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BIOLIFE SOLUTIONS INC(BLFS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 834365 BLFS stock profile & AI dashboard →

13F Pro Quality Score

62.1/100

Rank #732 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

75.8/100

Profitability

98.3/100

Balance Sheet

91.6/100

Earnings Quality

52.9/100

Free Cash Flow

61.5/100

Institutional Flow

22.3/100

Revenue Scale

16.8/100

Dilution Risk

7.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why BLFS Scores 62/100

exact factor attribution · 2026-09-11

BLFS's composite is driven by profitability and revenue growth, held back by scale and shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+7.2 pts

98th pct

Revenue growth

+5.2 pts

76th pct

Capital efficiency

+4.2 pts

92th pct

Earnings growth

+2.0 pts

90th pct

Free cash flow

+1.7 pts

62th pct

Earnings quality

+0.3 pts

53th pct

Institutional flow

-1.4 pts

22th pct

Shareholder dilution

-2.1 pts

8th pct

Scale

-5.0 pts

17th pct

Latest change (2026-08-06): 42 → 42 · ↓ Free cash flow 60→50

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

BLFS Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for BIOLIFE SOLUTIONS INC (BLFS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BLFS at 62.1/100 on a 32-signal composite quality model, placing it at rank #732 of 2,961 stocks — the top 25% of the AI-ranked universe. BLFS scores in the top quartile across profitability (98.3), balance sheet strength (91.6), revenue growth (75.8). Areas of concern include revenue scale (16.8) and institutional flow (22.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BIOLIFE SOLUTIONS INC reports quarterly revenue of $28.5M, net income of $45.1M, an operating margin of 6.0%. Top institutional holders of BLFS by reported 13-F value include T. Rowe Price Investment Management, BlackRock, Casdin Capital, based on the most recent SEC filings. BLFS trades on the Nasdaq exchange and files with the SEC under CIK 834365. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BLFS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIOLIFE SOLUTIONS INC directly from SEC EDGAR. BIOLIFE SOLUTIONS INC's 13F Pro composite quality score has ranged between 42 and 62 since 2026, currently 62.1 — an improving long-term trajectory across 48 quarterly and live scoring snapshots.

Revenue

Q2 2026

$28.5M

Net Income

Q2 2026

$45.1M

Free Cash Flow

Q2 2026

$5.3M

Operating Margin

Q2 2026

6.0%

ROIC

Q2 2026

1.6%

D/E Ratio

Q2 2026

0.00

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+28.9% YoY

$96.2MFY 2025

FY22 $76.2MFY23 $68.0MFY24 $74.6MFY25 $96.2M

Net Income

+77.2% YoY

$-4.6MFY 2025

FY22 $-139.8MFY23 $-68.0MFY24 $-20.2MFY25 $-4.6M

Operating Income

-270.8% YoY

$-16.6MFY 2025

FY22 $-5.9MFY23 $-17.2MFY24 $-4.5MFY25 $-16.6M

EPS (Diluted)

+77.3% YoY

$-0.10FY 2025

FY22 $-3.25FY23 $-1.55FY24 $-0.44FY25 $-0.10

Total Assets

+1.6% YoY

$405.9MFY 2025

FY22 $450.2MFY23 $412.7MFY24 $399.5MFY25 $405.9M

Total Debt

-62.8% YoY

$10.0MFY 2025

FY22 $27.4MFY23 $31.4MFY24 $26.9MFY25 $10.0M

Op. Cash Flow

+138.6% YoY

$20.1MFY 2025

FY22 $-8.5MFY23 $-12.5MFY24 $8.4MFY25 $20.1M

Free Cash Flow

+104.4% YoY

$10.6MFY 2025

FY22 $-18.9MFY23 $-18.9MFY24 $5.2MFY25 $10.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$96.2M +28.9%	$74.6M +9.7%	$68.0M -10.8%	$76.2M -36.0%	$119.2M +147.8%	$48.1M
Net Income	$-4.6M +77.2%	$-20.2M +70.3%	$-68.0M +51.4%	$-139.8M -1469.4%	$-8.9M -549.2%	$2.0M
Operating Income	$-16.6M -270.8%	$-4.5M +74.0%	$-17.2M -190.5%	$-5.9M +83.2%	$-35.2M -463.4%	$-6.2M
EPS (Diluted)	$-0.10 +77.3%	$-0.44 +71.6%	$-1.55 +52.3%	$-3.25 -1313.0%	$-0.23 -283.3%	$-0.06
Total Assets	$405.9M +1.6%	$399.5M -3.2%	$412.7M -8.3%	$450.2M -18.7%	$554.1M +135.9%	$234.8M
Total Debt	$10.0M -62.8%	$26.9M -14.5%	$31.4M +14.6%	$27.4M +239.5%	$8.1M +328.9%	$1.9M
Operating Cash Flow	$20.1M +138.6%	$8.4M +167.5%	$-12.5M -47.2%	$-8.5M -84.8%	$-4.6M -169.1%	$6.6M
Free Cash Flow	$10.6M +104.4%	$5.2M +127.6%	$-18.9M -0.0%	$-18.9M -45.4%	$-13.0M -377.1%	$4.7M

Get alerted when BLFS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BIOLIFE SOLUTIONS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BLFS

T. Rowe Price Investment Management, Inc.
$190.7M6,751,135 sh
BlackRock, Inc.
$180.0M6,375,545 sh
Casdin Capital, LLC
$131.5M4,655,000 sh
Invesco Ltd.
$63.3M2,240,423 sh
VANGUARD CAPITAL MANAGEMENT LLC
$55.5M1,964,084 sh
STATE STREET CORP
$46.8M1,655,927 sh
GEODE CAPITAL MANAGEMENT, LLC
$30.7M1,086,865 sh
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$30.5M1,079,270 sh
FRED ALGER MANAGEMENT, LLC
$30.4M1,077,577 sh
DIMENSIONAL FUND ADVISORS LP
$29.5M1,046,252 sh

Fund	Value	Shares
T. Rowe Price Investment Management, Inc.	$190.7M	6,751,135
BlackRock, Inc.	$180.0M	6,375,545
Casdin Capital, LLC	$131.5M	4,655,000
Invesco Ltd.	$63.3M	2,240,423
VANGUARD CAPITAL MANAGEMENT LLC	$55.5M	1,964,084
STATE STREET CORP	$46.8M	1,655,927
GEODE CAPITAL MANAGEMENT, LLC	$30.7M	1,086,865
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	$30.5M	1,079,270
FRED ALGER MANAGEMENT, LLC	$30.4M	1,077,577
DIMENSIONAL FUND ADVISORS LP	$29.5M	1,046,252

Companies Similar to BLFS

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

IRMD

IRADIMED CORP

AI score

Similar quality profile · 11 shared holders

T. Rowe Price Investment Management, Inc.Granahan Investment Management, LLC Ranger Investment Management, L.P.

AUPH

Aurinia Pharmaceuticals Inc.

AI score

Similar quality profile · 9 shared holders

Uniplan Investment Counsel, Inc.JACOBS LEVY EQUITY MANAGEMENT, INC DIAMOND HILL CAPITAL MANAGEMENT INC

CDNA

CareDx, Inc.

AI score

Similar quality profile · 9 shared holders

ROYCE & ASSOCIATES LP GAGNON SECURITIES LLC Gagnon Advisors, LLC

ARQT

Arcutis Biotherapeutics, Inc.

AI score

Similar quality profile · 8 shared holders

PEREGRINE CAPITAL MANAGEMENT LLC JACOBS LEVY EQUITY MANAGEMENT, INC CenterBook Partners LP

ADMA

ADMA BIOLOGICS, INC.

AI score

Similar quality profile · 8 shared holders

Ranger Investment Management, L.P.CenterBook Partners LP FOX RUN MANAGEMENT, L.L.C.

LGND

LIGAND PHARMACEUTICALS INC

AI score

Similar quality profile · 15 shared holders

Stephens Investment Management Group LLC NEXT CENTURY GROWTH INVESTORS LLC Granahan Investment Management, LLC

ZVRA

ZEVRA THERAPEUTICS, INC.

AI score

Similar quality profile · 1 shared holders

ROYCE & ASSOCIATES LP

ETON

Eton Pharmaceuticals, Inc.

AI score

Similar quality profile · 1 shared holders

Numerai GP LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BLFS on your watchlist

Track score changes the day BIOLIFE SOLUTIONS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BLFS a good stock to buy?

13F Pro's AI-powered analysis of BIOLIFE SOLUTIONS INC (BLFS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BLFS are available on the BLFS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BLFS is classified as a small company.

Which hedge funds own BLFS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BLFS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BIOLIFE SOLUTIONS INC's investment landscape.